▲ +10.81% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Aphria in the last 3 months. The average price target is C$18.34, with a high forecast of C$28.00 and a low forecast of C$10.75. The average price target represents a 10.81% upside from the last price of C$16.55.
The current consensus among 6 investment analysts is to hold stock in Aphria. This rating has held steady since January 2021, when it changed from a Buy consensus rating.
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.